Tourette Syndrome Tics
Conditions
Interventions
The study will be prospective in nature, being an open clinical trial with 10 patients of both sexes aged 18 years and over, diagnosed with Tourette Syndrome (TS) according to the Diagnostic and Stati
Sponsors
Hospital Universitário Oswaldo Cruz (HUOC) - Universidade de Pernambuco
Hospital Universitário Oswaldo Cruz (HUOC) - Universidade de Pernambuco
Eligibility
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Confirmed diagnosis of TT according to DSM-5 criteria; people of both genders; age 18 or over; availability to attend work on the days designated for carrying out the tasks rTMS sessions and for the application of assessment instruments
Exclusion criteria
Exclusion criteria: Lifetime diagnosis of bipolar disorder or schizophrenia according to the criteria from DSM-5; have any changes been made to psychotropic medications for continuous use in last four weeks; pregnancy; have any of the contraindications to rTMS: have aneurysm clips, have stents in the neck or brain, having undergone deep brain stimulation ever in your life, have electrodes to monitor brain activity, possess metal implants in the ears or eyes, have shrapnel or bullet fragments on or near the head, have facial tattoos with sensitive metallic or magnetic ink, have other metal devices or objects implanted in the head or nearby; have a report of a seizure in the last 12 months or have a diagnosis of epilepsy; have had any treatment with rTMS, electroconvulsive therapy (ECT) or stimulation transcranial direct current (tDCS), in the last 12 months; have reported abusive consumption of alcohol or other drugs in the last 6 months; have a diagnosis of any of the clinical comorbidities that may occur with psychiatric symptoms and may be a confounding factor: Lupus, thyroid changes, hormonal dysfunctions; have a history of any neurological comorbidity: Motor dyskinesia, paralysis brain, microcephaly or history of stroke; have a diagnosis of autism spectrum disorder (ASD)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: A sample predominantly composed of young males with complex tics was expected;Outcome found 1: A sample was obtained consisting predominantly of females of varying ages with complex tics;Expected outcome 2: A statistically significant reduction in the Yale Global Tic Severity Scale (YGTSS) total score was expected;Outcome found 2: A reduction in the total Yale Global Tic Severity Scale (YGTSS) score was observed, but it was not statistically significant, significant improvement occurred only when isolating the symptoms regarding motor tic severity and vocal tic interference;Expected outcome 3: Significant improvement in symptoms of depression and anxiety was expected;Outcome found 3: There was significant improvement in depressive and anxiety symptoms;Expected outcome 4: A correlation was expected between depressive and anxiety symptoms and tic severity;Outcome found 4: A strong correlation was observed between the improvement in anxiety and the reduction in tics;Expected outcome 5: No significant adverse effects were expected to be found;Outcome found 5: Adverse effects were mild and transient | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome: No secondary outcomes were expected;Outcome found: No secondary outcomes were found | — |
Countries
BR
Contacts
Public ContactMilton Mendonça Junior
Universidade de Pernambuco
Outcome results
None listed